European Archives - Page 897 of 1124 - European Medical Journal

Internet Trends Elucidate the Link Between Weather Conditions and Joint Pain

INDIVIDUALS with joint pain or arthritis have almost proverbially associated weather conditions with varying levels of pain. However, research undertaken…

Largest Ever Sample Study on Arthritis Yields Interesting Results

TODAY, the average American is twice as likely to be diagnosed with knee osteoarthritis than in the years leading up to World War II, according to a…

Introducing the European Medical Journal 2.3

United Kingdom, August 31, 2017: Welcome to this year’s third instalment of the European Medical Journal. This issue contains an abundance of…

European Medical Journal 2.3 2017

Welcome to this year’s third instalment of the European Medical Journal. The issue contains an abundance of high-quality, peer-reviewed articles…

How I Manage Myelofibrosis

Myelofibrosis (MF), either primary or secondary to polycythaemia vera or essential thrombocythaemia, is the most symptomatic and has the worst prognosis…

How I Diagnose Hypereosinophilic Syndromes

Hypereosinophilic syndromes are a group of disorders characterised by significant eosinophilia and organ damage.

Management of Multiply Relapsed Aggressive Non-Hodgkin Lymphoma: New Perspectives

Patients with refractory/relapsed (R/R) non-Hodgkin lymphoma (NHL) make up a very heterogeneous population with a poor life expectancy.

Redefining Later-Line Therapy in Metastatic Colorectal Cancer

The objective of the symposium was to provide an overview of the current treatment landscape in terms of later-line therapy in metastatic CRC (mCRC) and to discuss the evidence for the various options available.

Management of B-Cell Lymphoma: Where Are We Now and Where Are We Going?

The main objectives of the symposium were to explore the current developments in the diagnosis and treatment of non-Hodgkin lymphoma (NHL).

Editor’s Pick: Renal Involvement in Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disorder that represents almost 10% of haematologic malignancies.